
Immatics NV (IMTX) Stock Forecast & Price Target
Immatics NV (IMTX) Analyst Ratings
Bulls say
Immatics NV's robust pipeline, particularly with the anzu-cel asset, presents a compelling opportunity in the oncology market, bolstered by the ongoing Phase 3 SUPRAME study, which aims to demonstrate improved progression-free survival (PFS) over control. The company's impressive manufacturing success rate of 98% and shortened turnaround times further enhance its operational efficiency, essential for meeting high unmet medical needs in the second-line metastatic cancer segment. Additionally, the granting of Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA signifies a favorable regulatory pathway, reinforcing the potential for significant market success in this $2 billion opportunity within the U.S. marketplace.
Bears say
Immatics NV faces a challenging outlook due to underwhelming clinical results, specifically with Brenetafusp data showing only an 11% overall response rate and a 56% disease control rate in advanced melanoma patients, which may lead to downward revisions in risk-adjusted projections. Additionally, the company is exposed to multiple risks, including potential R&D and regulatory setbacks, competition, lower than expected product sales, and dilutive financing, which could further negatively impact financial performance. In a downside scenario, if critical endpoints are not met and pipeline programs do not yield value, the company could face a valuation as low as $3 per share within the next year.
This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.
Immatics NV (IMTX) Analyst Forecast & Price Prediction
Start investing in Immatics NV (IMTX)
Order type
Buy in
Order amount
Est. shares
0 shares